215 results about "Apoptosis" patented technology

The application discloses a photosensitizer conjugate for targeted treatment of tongue squamous cell carcinoma and a preparation method and application thereof, and belongs to the technical field of biological medicines. A novel PROTAC-PDT conjugate Gef-PRO-SS-TPE is synthesized, and the compound connects a PROTAC molecule Gef-PRO targeting EGFR and an AIE photosensitizer TPE derivative through a breakable disulfide bond. On one hand, Gef-PRO can specifically degrade EGFR and block tumor cell proliferation signals; on the other hand, the TPE derivative can generate ROS under light conditions and induce cell apoptosis. More importantly, the disulfide bond can be broken in response to high concentrations of glutathione (GSH) in tumor cells, realizing controllable release of Gef-PRO and TPE molecules, so as to exert a synergistic anti-tumor effect.

The present application relates to a kind of hydrolysis targeting chimera based on artificial antibody and its preparation method and application.The hydrolysis targeting chimera is composed of artificial gold antibody and molecule that can activate cell degradation mechanism, the artificial gold antibody is composed of gold nanoparticle and polypeptide coupled on the surface of gold nanoparticle, the molecule that can activate cell degradation mechanism is coupled on the surface of gold nanoparticle.The hydrolysis targeting chimera can simultaneously bind target protein and activate cell degradation mechanism, with the performance of strong specific recognition target protein, and high stability, orientation controllable.At the same time, the hydrolysis targeting chimera can also play the molecule of activation cell degradation mechanism, such as lysosome sorting signal motif, coupled on the surface, induce clathrin-mediated endocytosis, transport the complex of target protein and chimera to lysosome and degrade.The hydrolysis targeting chimera can play multi-mode cancer treatment effect by synergistic inhibition of tumor cell proliferation, invasion pathway and apoptosis activation.

This invention relates to diselenylene-bridged mesoporous silica nanoparticles loaded with baicalin and their applications. The invention constructs a ROS-responsive, microglia-inspired Ba@Se-MSN&BV2 nanoplatform targeting the secondary phase of spinal cord injury. The BV2 cell membrane-mediated enrichment at the injury site, combined with the diselenylene-triggered, on-demand release of baicalin, enables targeted intervention in a highly oxidative and pro-inflammatory microenvironment. In vitro and in vivo studies show that Ba@Se-MSN&BV2 can alleviate oxidative stress and mitochondrial dysfunction, inhibit apoptosis, promote axonal and neuronal survival, and improve motor circuit function. This invention provides a new therapeutic target and research direction for neuroinflammatory injuries driven by redox homeostasis disruption, with significant clinical application prospects and social value.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

This invention discloses a phosphorylated diamine morpholino oligonucleotide drug that regulates PAPOLA expression and its application, belonging to the field of biomedical technology. The nucleotide sequence of the drug is shown in SEQ ID NO:1, targeting the coding region of human PAPOLA mRNA. The formulation is a lyophilized powder for injection, with excipients including mannitol and phosphate buffer. This invention also discloses the application of this drug in the preparation of a treatment for gastric cancer, specifically advanced gastric cancer with high PAPOLA expression. The drug is administered intravenously at a dose of 8-12 mg / kg every 3 days. Its mechanism of action is to block PAPOLA protein translation, inhibit the G1 / S phase transition of gastric cancer cells, and induce apoptosis. In vitro and in vivo experiments have confirmed that this drug can specifically inhibit the proliferation and growth of gastric cancer cells, providing a new treatment option for advanced gastric cancer.

The application discloses application of a cerium monatomic functional material in preparation of a tumor radiotherapy sensitizer. SA In the material, cerium is dispersed on a nitrogen-doped carbon carrier in a monatomic form and forms a stable coordination structure with N / O. The application determines the structure-activity relationship of the unique physical and chemical structure and multiple enzyme activities, verifies the radiotherapy sensitization effect and biological safety in and out of the body. The material has multiple enzyme activities such as simulating peroxidase and glutathione oxidase, can efficiently catalyze ROS and consume GSH, and enhances DNA damage and apoptosis induced by ionizing radiation. In vitro clone formation experiments show that the radiotherapy sensitization ratio reaches 1.38, which is better than that of CeO2 nano clusters (1.17). In vivo experiments on tumor-bearing mice prove that the material combined with radiotherapy can significantly inhibit tumor growth, prolong survival time, and has good biocompatibility. The application provides a new strategy of high efficiency and low toxicity for tumor radiotherapy sensitization, and has a good clinical application prospect.

The application discloses a prenylated polyketide compound, a preparation method and application thereof, and the prenylated polyketide compound is separated from rice fermented with Xylaria nigriplicata. The neuroprotective effect of the prenylated polyketide compound on glutamate-induced excitotoxicity of PC12 cells is clarified through comprehensive evaluation of cell viability, apoptosis and key oxidative stress markers.

Disclosed herein are multi-specific binding polypeptide molecules (e.g., multi-specific antibodies) that are capable of interacting with TNF-related apoptosis-inducing ligand (TRAIL) receptors and cell-specific antigens. In some embodiments, methods for using the multi-specific binding polypeptides (e.g., multi-specific antibodies) to treat one or more diseases or conditions (e.g., cancer) are also described herein.

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

The present application relates to a kind of microglial cell P2Y6R target point inhibitor and its application, belong to biological medicine technical field.For the problems such as lack of effective treatment means for retinal pigment degeneration, abnormal activation of microglial cell accelerates course and lack of specific intervention target point, the application of inhibitor with P2Y6R as target point in preparation treatment retinal pigment degeneration drug is proposed, especially siRNA and shRNA for knocking down microglial cell P2ry6 gene are provided, and AAV vector containing microglial cell specific promoter is constructed, the specific silencing of P2ry6 in retina is realized.The present application can significantly inhibit abnormal activation of microglial cell and inflammatory response, reduce photoreceptor apoptosis, improve retina structure and visual function, and provide a new strategy for targeted treatment of retinal pigment degeneration.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

This invention belongs to the field of tumor immunotherapy and provides the application of Hdac3 gene knockout formulations or Ikkα gene knockout formulations in the preparation of drugs that inhibit tumor metastasis. The research results of this invention show that Hdac3 and Ikkα gene mutations significantly inhibit lung tumor metastasis and prolong the survival of mice, and this metastasis inhibition is independent of T, B, and NK cells. Simultaneously, this invention also discovers that Hdac3 and Ikkα mutations inhibit lung tumor metastasis by affecting the sensitivity of tumor cells to tumor necrosis factor, making tumor cells more susceptible to apoptosis, thereby providing a method for sustained in vivo killing of tumor cells. This invention also provides a mutant vector, which exhibits good anti-tumor metastasis effects.

The present application belongs to the field of photochemical therapy, and particularly relates to a method for photochemical treatment of riboflavin based on multi-wavelength LED and application thereof in treatment of graft-versus-host disease. The present application selects different wavelength LED combinations as light sources to optimize the riboflavin photochemical method, controls the light intensity at 1000-25000 μW / cm², controls the irradiation time at 5-15 minutes, and controls the riboflavin concentration at 20-150 μM, thereby significantly improving the photochemical reaction effect. The method can efficiently induce PBMC apoptosis in a plasma environment, significantly reduces the levels of key pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-γ, and has no significant influence on platelets, hemoglobin and blood clotting function, thereby providing a safe and controllable new cell preparation method for GVHD treatment.

The application relates to the field of nanobiomedical technology, and particularly relates to application of polyethylene glycol modified black phosphorus nanosheets in prevention and treatment of acute liver injury. The polyethylene glycol modified black phosphorus nanosheets not only have a significant active oxygen scavenging capacity, but also have calcium ion chelation and buffering capacity, can simultaneously regulate intracellular oxidation-reduction homeostasis and calcium homeostasis, inhibit intracellular calcium overload, especially mitochondrial calcium overload, maintain mitochondrial function, and further reduce liver cell damage, apoptosis and inflammatory response, and play a liver protection role. The application finds that the black phosphorus nanosheets are used in calcium ion chelation and inhibition of cell calcium overload, and breaks through the limitation that the black phosphorus nanosheets are mainly used as active oxygen scavenging materials in the prior art. The material can also adsorb copper ions and realize radioactivity copper labeling without chelating agent, and can be used for liver enrichment tracing and integrated diagnosis and treatment application. The material has a significant protective effect on paracetamol-induced acute liver injury.

Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and / or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

This invention is related to the fields of medical biotechnology, nanobiotechnology, and nanomedicine. It involves a nanomedicine product that can release HOC1 (hypochlorous acid) at the tumor site in a controlled manner to treat lung cancer. HOC1 is a potent antimicrobial and antitumor agent that can target tumor tissues while minimizing damage to healthy tissues. The produced nanoparticles have a two-layer structure: the inner layer contains alginate, PFP (perfluoropentane), and Ca(OCl)2 to release HOC1, and the outer layer has a chitosan coating with folate and salicylic acid for targeting and proton release. The production process involves nanoemulsion and coating with the ionic gelation technique. When the nanoparticles are delivered to the lungs and targeted to cancer cells with folate, ultrasound radiation triggers the release of HOC1 to induce apoptosis and destroy cancer cells effectively, reducing side effects and improving treatment outcomes for lung cancer patients.

This invention provides biomimetic nanopharmaceuticals for mitochondrial dysfunction, methods for producing the same, and applications. [Solution] The biomimetic nanodrug comprises an RGD-engineered exosome as a carrier, decalinium chloride modified on the surface of the carrier, and oxaliplatin encapsulated inside the carrier. The biomimetic nanodrug of the present invention (OXA@Exo-RD) protects cargoes that induce mitochondrial dysfunction in the blood circulation process, sequentially increasing the accumulation of mitochondria in the cargoes by targeting them. Cargo 1 (DQA) induces oxidative stress, triggering mitochondrial-mediated apoptosis and mitochondrial dysfunction, while cargo 2 (OXA) disrupts mitochondrial DNA and inhibits the initiation of DNA repair, thereby improving chemotherapy resistance. Both cargoes synergistically overcome CRC drug resistance and inhibit its migration.

Provided herein are systems, methods, and compositions for a Remote-Controlled Alteration / Induction of Cellular Apoptosis. In one embodiment, the method comprises radio- controlled mRNA therapy to treat cancer.

This invention discloses a method for preparing fucoidan from *Sargassum hemifolia* and its application in the preparation of anti-hepatocellular carcinoma drugs. Experimental results show that *Sargassum hemifolia* fucoidan Fb has a strong inhibitory effect on HepG2 hepatocellular carcinoma cells, significantly stronger than the inhibitory effects of *Sargassum henryi* polysaccharide Fh and *Sargassum fusiforme* polysaccharide SFPS on HepG2 hepatocellular carcinoma cells. After treatment of HepG2 hepatocellular carcinoma cells with *Sargassum hemifolia* fucoidan DF1 and DF2, apoptosis is ultimately induced through the interaction and cooperation of exogenous (death receptor pathway) and endogenous (mitochondrial pathway). *Sargassum hemifolia* fucoidan possesses strong antitumor activity and therefore can be used to prepare anti-hepatocellular carcinoma drugs.

This invention discloses butylphthalide nanoparticles, comprising: a layered double hydroxide and butylphthalide, wherein the butylphthalide is loaded onto the layered double hydroxide. This invention also discloses a method for preparing the above-mentioned butylphthalide nanoparticles, comprising the following steps: mixing the layered double hydroxide, butylphthalide, and water, adsorbing, separating the solid and liquid phases, and drying to obtain butylphthalide nanoparticles. This invention further discloses the application of the above-mentioned butylphthalide nanoparticles in the preparation of drugs for treating acute renal ischemia-reperfusion injury. This invention also discloses a drug for treating acute renal ischemia-reperfusion injury, comprising: the above-mentioned butylphthalide nanoparticles and pharmaceutically acceptable excipients. The butylphthalide nanoparticles of this invention have high drug loading capacity, good stability, and can target and activate the PI3K-AKT signaling pathway, effectively inhibit HK-2 cell apoptosis and oxidative stress, restore mitochondrial function, and improve renal ischemia-reperfusion injury.

This invention discloses a novel application of the RNA-binding protein HNRNPA1 in regulating copper death in synovial fibroblasts of rheumatoid arthritis (RA-FLS). Overexpression of HNRNPA1 recognizes and binds to the m6A modification site of SLC3A2 mRNA, enhancing its transcript stability, restoring the expression of SLC3A2 and copper death-related proteins, reducing MDA levels, increasing copper ion concentration and the activity of antioxidant enzymes SOD and POD, thereby repairing mitochondrial ultrastructural damage, inhibiting abnormal cell proliferation, and inducing apoptosis. Reversal experiments confirmed that knocking down SLC3A2 reverses the above effects, indicating that SLC3A2 is a core downstream target of HNRNPA1-mediated copper death. This invention reveals for the first time the decisive role of the HNRNPA1-SLC3A2-copper death axis in the pathological phenotype of RA-FLS, providing a new target for molecular intervention in rheumatoid arthritis.

1. The name of the design product: multifunctional enzyme label instrument. 2. The use of the design product: for nucleic acid, protein concentration, enzyme activity analysis and other conventional molecular detection; signal transduction research, cell signal event active oxygen, modification detection; cell viability, apoptosis, killing and other overall level analysis. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

A method for the precise cellular destruction of an oncogenic non-coding RNA with a RNA-binding small molecule conjugated with bleomycin A5 is described. The method affords reversal of phenotype. Bleomycin A5 was coupled to an RNA-binding molecule that selectively binds the microRNA-96 hairpin precursor (pri-miR-96). By coupling of bleomycin A5's free amine to the RNA-binding molecule, its affinity for binding to pri-miR-96 is >100-fold stronger than to DNA. The conjugate compound selectively cleaves pri-miR-96 in triple negative breast cancer (TNBC) cells. Selective cleavage of pri-miR-96 enhances expression of FOXO1 protein, a pro-apoptotic transcription factor that miR-96 silences, and triggers apoptosis in TNBC cells. No effects were observed in healthy breast epithelial cells. This method provides programmable control for targeting RNA through the selection of an RNA-binding molecule / bleomycin A5 conjugate and provides a facile method of mapping the cellular binding sites of an RNA-binding molecule.

This invention provides a method for constructing a visualized mouse model characterizing hepatocyte necrosis and apoptosis, belonging to the field of biomedical technology. The invention involves disassembling firefly luciferase (Fluc) into inactive N-terminal (Nluc) and C-terminal (Cluc) fragments, which are then fused and expressed at specific locations on the MLKL molecule, forming two independent plasmid vectors, MLKL-Nluc and MLKL-Cluc. These two plasmid vectors are then injected into mouse hepatocytes via tail vein high-pressure hydrodynamic injection to construct the visualized mouse model characterizing hepatocyte necrosis and apoptosis. This invention allows for non-invasive and dynamic monitoring of the execution process of necrosis and apoptosis—MLKL oligomerization—in animal models, providing a powerful and specific tool that fills the technological gap in real-time visual monitoring of necrosis and apoptosis in pan-apoptotic research.

This invention discloses a Polygonatum sibiricum vesicle preparation for treating premature ovarian failure, its preparation method, and its application. The preparation method includes: cleaning Polygonatum sibiricum, juicing, filtering to remove residue, and collecting the juice; subjecting the juice to gradient centrifugation to remove residual plant tissue, plant cells, and plant cell debris; then using an extraction reagent for stepwise precipitation, collecting the precipitate, and resuspending it to obtain the final product. The Polygonatum sibiricum vesicle preparation prepared by this invention can be efficiently taken up by ovarian granulosa cells. It effectively treats premature ovarian failure by activating the Nrf2 signaling pathway, upregulating antioxidant enzyme expression, scavenging reactive oxygen species, restoring mitochondrial membrane potential, inhibiting apoptosis, and restoring the expression levels of estrogen, follicle-stimulating hormone, and anti-Müllerian hormone. The preparation method of this invention is standardized, biocompatible, and safe, and has broad clinical application prospects.

This invention discloses the application of a "Super Brain-Boosting Capsule," belonging to the field of pharmaceutical technology. The Super Brain-Boosting Capsule is used in the preparation of drugs for treating Alzheimer's disease. The capsule enhances the mitochondrial membrane potential of Glu-treated HT22 cells by inhibiting ferroptosis. At the transcriptional level, the capsule activates the expression of key Nrf2 / HO-1 / GPX4 signaling molecules NRF2, HO-1, GPX4, SLC7A11, ACSL4, FTH1, and FPN1, while reversing the expression of Bcl-2, Caspase-3, and Caspase-9 to inhibit apoptosis in AD cells. This invention reveals that the Super Brain-Boosting Capsule, based on the Nrf2 / HO-1 / GPX4 pathway, inhibits Glu-induced ferroptosis in HT22 cells, which can treat Alzheimer's disease. This invention provides experimental evidence and direction for the further development of the Super Brain-Boosting Capsule in the prevention and treatment of Alzheimer's disease and other neurodegenerative diseases.